HLS Therapeutics Inc.
HLS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 56.62M | 56.94M | 58.89M | 60.79M | 63.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.62M | 56.94M | 58.89M | 60.79M | 63.07M |
| Cost of Revenue | 14.66M | 14.36M | 14.23M | 13.72M | 13.20M |
| Gross Profit | 41.96M | 42.59M | 44.67M | 47.07M | 49.88M |
| SG&A Expenses | 26.93M | 26.75M | 27.30M | 28.17M | 28.29M |
| Depreciation & Amortization | 22.72M | 24.33M | 27.03M | 29.54M | 31.94M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.31M | 65.43M | 68.55M | 71.42M | 73.42M |
| Operating Income | -7.69M | -8.49M | -9.66M | -10.63M | -10.35M |
| Income Before Tax | -15.58M | -17.97M | -20.39M | -28.11M | -27.80M |
| Income Tax Expenses | 4.07M | 4.06M | 3.70M | -261.00K | -272.00K |
| Earnings from Continuing Operations | -19.66 | -22.03 | -24.09 | -27.85 | -27.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.66M | -22.03M | -24.09M | -27.85M | -27.53M |
| EBIT | -7.69M | -8.49M | -9.66M | -10.63M | -10.35M |
| EBITDA | 14.99M | 15.77M | 17.30M | 18.84M | 21.52M |
| EPS Basic | -0.72 | -0.69 | -0.75 | -0.87 | -0.85 |
| Normalized Basic EPS | -0.43 | -0.41 | -0.42 | -0.43 | -0.42 |
| EPS Diluted | -0.73 | -0.70 | -0.76 | -0.87 | -0.86 |
| Normalized Diluted EPS | -0.43 | -0.41 | -0.42 | -0.43 | -0.42 |
| Average Basic Shares Outstanding | 125.80M | 127.34M | 127.79M | 128.31M | 128.73M |
| Average Diluted Shares Outstanding | 125.80M | 127.34M | 127.79M | 128.31M | 128.73M |
| Dividend Per Share | -- | 0.00 | 0.00 | 0.04 | 0.08 |
| Payout Ratio | -- | 0.00% | 0.00% | -4.37% | -8.71% |